AIMS: This study is a real world, observational study evaluating the treatment persistence of oral antiplatelet (OAP) therapy during a one-year follow-up in @entity1 after an @entity1187 ( @entity1187 ). METHODS AND RESULTS: Data on diagnosis, comorbidities, follow-up, OAP treatment, reasons, and decision maker for treatment discontinuation in @entity1 who were discharged from a hospital in Belgium after an @entity1187 between 1 July 2012 and 1 June 2013 were collected by cardiologists from 18 centres, up to 360 days from discharge. Out of the 671 @entity1 surveyed, 295 @entity1 were included in the persistence analysis. The remainder was excluded from the analysis due to the lack of precise information on OAP stopping date. The proportion of @entity1 still using OAPs after 90, 180, 270, and 360 days was 92, 89, 83, and 73%, respectively. OAP persistence was higher for @entity1 treated with @entity3076 or @entity3077 . At 360 days, 79% of @entity1 with a @entity583 ( @entity583 ) and 66% of @entity1 with a non- @entity583 were still adhering to the prescribed course of treatment. Among the 79 @entity1 with early treatment discontinuation, the mean treatment duration was 197.0        125.18 days. The main decision taker in premature treatment cessation was the cardiologist (31% of cases), while the most frequently cited reasons included surgery (25%) and perceived high bleeding risk (19%). CONCLUSION: Treatment persistence with OAPs after @entity1187 in Belgium is high throughout the recommended period. Discontinuation was observed more often in @entity1 treated with @entity1397 and was mainly initiated by the cardiologist.

Real world insights on the initiation and treatment duration of oral antiplatelets in XXXX : a retrospective cohort study.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1187 :: ('MESH:D054058', 'Disease') :: ['ACS', 'acute coronary syndrome'] @entity3076 :: ('MESH:C408153', 'Chemical') :: ['prasugrel'] @entity1397 :: ('MESH:C055162', 'Chemical') :: ['clopidogrel'] @entity3077 :: ('MESH:C503700', 'Chemical') :: ['ticagrelor'] @entity583 :: ('MESH:D009203', 'Disease') :: ['STEMI', 'ST-segment elevation myocardial infarction']
@entity1187 :: (MESH:D054058,Disease) :: ['acute coronary syndromes']
